Labcorp Holdings Inc.

LSE:0JSY Stock Report

Market Cap: US$19.2b

Labcorp Holdings Valuation

Is 0JSY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0JSY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0JSY ($229.98) is trading below our estimate of fair value ($723.53)

Significantly Below Fair Value: 0JSY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0JSY?

Key metric: As 0JSY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0JSY. This is calculated by dividing 0JSY's market cap by their current earnings.
What is 0JSY's PE Ratio?
PE Ratio44.1x
EarningsUS$435.50m
Market CapUS$19.19b

Price to Earnings Ratio vs Peers

How does 0JSY's PE Ratio compare to its peers?

The above table shows the PE ratio for 0JSY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average27.6x
IDHC Integrated Diagnostics Holdings
15.9x21.5%US$255.5m
SN. Smith & Nephew
35.4x22.7%UK£8.6b
MDC Mediclinic International
21.9x10.7%UK£3.7b
CTEC ConvaTec Group
37.1x20.2%UK£4.5b
0JSY Labcorp Holdings
44.1x21.9%US$19.2b

Price-To-Earnings vs Peers: 0JSY is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the peer average (29.4x).

Price to Earnings Ratio vs Industry

How does 0JSY's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0JSY 44.1xIndustry Avg. 18.2xNo. of Companies8PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0JSY is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is 0JSY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0JSY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio44.1x
Fair PE Ratio43.3x

Price-To-Earnings vs Fair Ratio: 0JSY is expensive based on its Price-To-Earnings Ratio (44.1x) compared to the estimated Fair Price-To-Earnings Ratio (43.3x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0JSY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$229.98
US$262.88
+14.3%
6.6%US$293.00US$231.00n/a16
Dec ’25US$241.16
US$261.06
+8.3%
6.4%US$293.00US$231.00n/a16
Nov ’25US$229.22
US$260.75
+13.8%
6.5%US$293.00US$231.00n/a16
Oct ’25US$219.79
US$252.00
+14.7%
7.9%US$282.00US$199.99n/a16
Sep ’25US$229.05
US$250.13
+9.2%
8.7%US$277.00US$199.99n/a15
Aug ’25US$231.25
US$240.60
+4.0%
8.8%US$275.00US$199.99n/a15
Jul ’25US$203.12
US$237.60
+17.0%
7.3%US$262.00US$210.00n/a15
Jun ’25US$192.43
US$238.47
+23.9%
6.7%US$262.00US$210.00n/a15
May ’25US$201.65
US$239.57
+18.8%
6.8%US$262.00US$210.00n/a16
Apr ’25US$217.79
US$244.87
+12.4%
6.0%US$270.00US$220.00n/a15
Mar ’25US$216.78
US$245.07
+13.0%
6.0%US$270.00US$220.00n/a15
Feb ’25US$223.71
US$241.28
+7.9%
6.8%US$270.00US$215.00n/a14
Jan ’25US$227.25
US$242.28
+6.6%
6.3%US$270.00US$215.00n/a14
Dec ’24US$219.15
US$239.92
+9.5%
7.1%US$270.00US$210.00US$241.1614
Nov ’24US$204.86
US$239.56
+16.9%
7.5%US$270.00US$210.00US$229.2214
Oct ’24US$203.81
US$245.85
+20.6%
8.6%US$285.00US$210.00US$219.7914
Sep ’24US$212.17
US$249.28
+17.5%
7.5%US$285.00US$215.00US$229.0514
Aug ’24US$211.71
US$255.64
+20.8%
9.0%US$290.00US$215.00US$231.2514
Jul ’24US$239.41
US$269.14
+12.4%
7.2%US$290.00US$233.00US$203.1214
Jun ’24US$214.45
US$271.86
+26.8%
6.1%US$290.00US$235.00US$192.4314
May ’24US$225.99
US$276.50
+22.3%
6.7%US$300.00US$235.00US$201.6514
Apr ’24US$227.86
US$284.31
+24.8%
4.3%US$300.00US$260.00US$217.7913
Mar ’24US$239.25
US$285.54
+19.3%
4.6%US$304.00US$260.00US$216.7813
Feb ’24US$251.02
US$279.15
+11.2%
7.6%US$315.00US$250.00US$223.7113
Jan ’24US$234.66
US$276.23
+17.7%
7.7%US$315.00US$250.00US$227.2513
Dec ’23US$242.94
US$278.15
+14.5%
7.2%US$315.00US$250.00US$219.1513

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 20:57
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Labcorp Holdings Inc. is covered by 48 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian Kemp DolliverAvondale Partners
Eric ColdwellBaird